Potential Applications of Endo-?-N-Acetylglucosaminidases From Bifidobacterium longum Subspecies infantis in Designing Value-Added, Next-Generation Infant Formulas

Basit Öğe Kaydı
dc.authoridKaplan, Merve/0000-0002-3322-0988
dc.authoridKARAV, SERCAN/0000-0003-4056-1673
dc.authoridSAHUTOGLU, Arif Sercan/0000-0003-1183-3553
dc.contributor.authorDuman, Hatice
dc.contributor.authorKaplan, Merve
dc.contributor.authorArslan, Aysenur
dc.contributor.authorSahutoglu, Arif Sercan
dc.contributor.authorKayili, Haci Mehmet
dc.contributor.authorFrese, Steven A.
dc.contributor.authorKarav, Sercan
dc.date.accessioned2024-09-29T16:08:01Z
dc.date.available2024-09-29T16:08:01Z
dc.date.issued2021
dc.departmentKarabük Üniversitesien_US
dc.description.abstractHuman milk is the optimal source of infant nutrition. Among many other health benefits, human milk can stimulate the development of a Bifidobacterium-rich microbiome through human milk oligosaccharides (HMOs). In recent years, the development of novel formulas has placed particular focus on incorporating some of the beneficial functional properties of human milk. These include adding specific glycans aimed to selectively stimulate the growth of Bifidobacterium. However, the bifidogenicity of human milk remains unparalleled. Dietary N-glycans are carbohydrate structures conjugated to a wide variety of glycoproteins. These glycans have a remarkable structural similarity to HMOs and, when released, show a strong bifidogenic effect. This review discusses the biocatalytic potential of the endo-beta-N-acetylglucosaminidase enzyme (EndoBI-1) from Bifidobacterium longum subspecies infantis (B. infantis), in releasing N-glycans inherently present in infant formula as means to increase the bifidogenicity of infant formula. Finally, the potential implications for protein deglycosylation with EndoBI-1 in the development of value added, next-generation formulas are discussed from a technical perspective.en_US
dc.description.sponsorshipEvolve Biosystems, Inc.en_US
dc.description.sponsorshipThe authors thank RMD for critical reading of the manuscript and feedback. SK and SF have received funding from Evolve Biosystems, Inc., a company focused on the infant gut microbiome. SK has received funding from Uluova Sut Ticaret A.S (Uluova Milk Trading Co.), a company focused on the production of colostrum and lactoferrin.en_US
dc.identifier.doi10.3389/fnut.2021.646275
dc.identifier.issn2296-861X
dc.identifier.pmid33898500en_US
dc.identifier.scopus2-s2.0-85105104117en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.3389/fnut.2021.646275
dc.identifier.urihttps://hdl.handle.net/20.500.14619/7316
dc.identifier.volume8en_US
dc.identifier.wosWOS:000642518900001en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherFrontiers Media Saen_US
dc.relation.ispartofFrontiers in Nutritionen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjecthuman milk oligosaccharidesen_US
dc.subjectN-glycansen_US
dc.subjectendo-? -N-acetylglucosaminidaseen_US
dc.subjectbifidobacteriaen_US
dc.subjectinfant formulaen_US
dc.titlePotential Applications of Endo-?-N-Acetylglucosaminidases From Bifidobacterium longum Subspecies infantis in Designing Value-Added, Next-Generation Infant Formulasen_US
dc.typeReviewen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu